New research suggests that people who come off new slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise programs.
Published data in a prominent health publication demonstrates that while obese people can lose a large proportion of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"People buying these treatments need to be cognizant of the danger of quick rebound weight gain when the medication concludes," warns lead investigator Dr. Susan Jebb.
Such speed of recovery implies a return to starting weight within about 18 months.
Comparing Approaches
The study, which reviewed 37 of studies involving over 9,000 of participants, contrasted the results of the injectable medications with older methods.
Scientists point out that people who shed pounds through lifestyle changes alone typically experience a slower weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Regain
Nutrition scientists propose the way of the jabs accounts for the heightened weight return.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to appetite is uncontrolled, making overeating far more likely."
An Ongoing Issue?
The NHS suggest the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts contend that, given the significant potential of relapse, the treatment is often ongoing.
This view is reinforced by pharmaceutical companies, who note that the results "underscore the persistent character of obesity," akin to managing diseases like diabetes.
Patient Experiences
Users who have stopped the jabs describe a sudden resurgence of appetite.
"It was like something activating and you become starving," described an individual.
This challenge is worsened if patients have not established lasting lifestyle or habit changes during therapy.
Widespread Use
Recent estimates show that a significant number of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Use is more common among women than males.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while the jabs are potent agents for weight loss, they are not a permanent fix and long-term success likely depends on ongoing behavioural management.
